BioLineRX, Merck to study drug combination for treatment of pancreatic cancer
The companies will partner in a phase 2 study to evaluate the safety and efficacy of the combination of BioLineRx’s BL-8040 CXCR4 antagonist and Merck’s Keytruda humanized monoclonal
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.